Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
1.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

9.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.8K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

Distinct immune landscapes characterize highly versus minimally invasive brain metastases.

JCI insight·2026
Same author

Mitochondrial ETF insufficiency drives neoplastic growth by selectively optimizing cancer bioenergetics.

eLife·2026
Same author

Erratum: Publisher Correction: Assessing the Relationship Between Bladder Cancer Cell Contractile Phenotypes and Their Invasive Properties.

Cellular and molecular bioengineering·2026
Same author

Assessing the Relationship Between Bladder Cancer cell Contractile Phenotypes and their Invasive Properties.

Cellular and molecular bioengineering·2026
Same author

KDM3A catalyses the oxidation of acetyl-lysine to hydroxyacetyl-lysine on histone H3K9.

Nature chemistry·2026

Related Experiment Video

Updated: Mar 15, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

20.0K

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway.

Mélissa Carbonneau1,2, Laurence M Gagné3, Marie-Eve Lalonde2

  • 1Département de Biochimie et Médecine Moléculaire, Université de Montréal, C.P. 6128, Succursale Centre-Ville, Montréal, Quebec, Canada H3C 3J7.

Nature Communications
|September 15, 2016
PubMed
Summary

Mutant isocitrate dehydrogenases (IDH1/2) drive cancer by producing 2-hydroxyglutarate (2HG). This oncometabolite activates mTOR signaling by inhibiting KDM4A, revealing a new cancer mechanism.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

891
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K

Related Experiment Videos

Last Updated: Mar 15, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

20.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

891
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K

Area of Science:

  • Biochemistry
  • Oncology
  • Metabolic pathways

Background:

  • Mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) are linked to cancer.
  • IDH1/2 mutations lead to the production of the oncometabolite 2-hydroxyglutarate (2HG).
  • Aberrant cellular metabolism is increasingly recognized as a driver of carcinogenesis.

Purpose of the Study:

  • To elucidate the molecular mechanism by which mutant IDH1/2 promotes cancer.
  • To investigate the link between 2HG production and mTOR pathway activation.
  • To identify novel therapeutic targets in IDH1/2-mutated cancers.

Main Methods:

  • Investigated the effect of 2HG on KDM4A activity.
  • Examined the interaction between KDM4A and DEPTOR.
  • Assessed the impact of KDM4A depletion on DEPTOR stability.
  • Analyzed mTOR pathway activation in the context of IDH1/2 mutations.

Main Results:

  • Mutant IDH1/2-generated 2HG inhibits KDM4A, an αKG-dependent lysine demethylase.
  • KDM4A inhibition leads to mTORC1/2 activation.
  • KDM4A interacts with DEPTOR, and KDM4A depletion reduces DEPTOR stability.
  • This pathway provides a novel link between TCA cycle defects and mTOR activation.

Conclusions:

  • Mutant IDH1/2 promotes oncogenesis through 2HG-mediated mTOR activation via KDM4A inhibition.
  • This discovery offers a new molecular mechanism for IDH1/2-driven cancers.
  • Targeting this pathway could offer therapeutic strategies for gliomas and acute myeloid leukemias.